Navigation Links
Launch of Fountain Healthcare Partners, a Life Science Venture Capital Firm
Date:4/29/2008


DUBLIN and NEW YORK, April 29 /PRNewswire/ --

- Announces First Close of EUR75 ($117) Million

- Largest Life Science Venture Capital ("VC") Fund Launched in Ireland

- One of the Largest Emerging Manager VC Funds Raised in the Life

Science Sector Globally

- Headquartered in Dublin, Fountain Will Invest the Majority of its

Capital in Europe With a Primary Focus on Ireland

Fountain Healthcare Partners ("Fountain") today launches and announces the first close of its inaugural fund, Fountain Healthcare Partners I, with EUR75 ($117) million of committed capital.

The fund is the largest dedicated life science (specialty pharmaceuticals, biotechnology, medical devices and diagnostics) venture capital ("VC") firm based in Ireland. It is also one of the largest emerging manager VC funds raised in the life science sector globally in the past 2 years.

Fountain will invest the majority of its capital in Europe and will have a strong emphasis on the life science sector in Ireland. The first close significantly exceeded initial expectations and Fountain is now targeting approximately EUR100 million in commitments at its final close.

Over 90% of the capital invested in the fund was sourced from institutional investors of which 75% are Irish based. Institutional investors include the European Investment Fund, the National Pension Reserve Fund and Enterprise Ireland. A select number of high net worth individual investors also participated. "We have been very pleased with the level and quality of investor participation in the first close. There was clear support for our investment strategy, and we significantly exceeded our original first close target," said Dr Manus Rogan, a founding partner at Fountain.

Fountain is a bi-located fund with a main office in Dublin and a second office in New York. "The purpose of our New York office is to maintain on-the-ground connectivity with the US life-scien
'/>"/>

SOURCE Fountain Healthcare Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
2. Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory
3. The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring Last Lecturer Dr. Randy Pausch
4. Hovione Launches New Website
5. International Council on Nanotechnology launches global research needs assessment
6. Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
7. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
8. Botaneco Announces Launch of Second Generation Oleosome Product
9. Novagali Pharma Announces the Launch of Cationorm(R)
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SEATTLE , March 3, 2015 Adaptive ... Group CFO, is joining its Board of Director as ... financial officer at Zillow Group, Chad oversees all finance, ... Chad built the company,s core finance, treasury and accounting ... IPO and nine acquisitions. In 2013, he was named ...
(Date:3/3/2015)... N.J. , March 3, 2015  Regenicin, Inc. ... company specializing in the development of and commercialization of ... tissues and organs, announced today that it has received ... with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... the Agreement, Amarantus made the final payments due to ...
(Date:3/3/2015)... BOSTON, MA (PRWEB) March 03, 2015 ... Print Supply Chain, today announced the expansion of its ... quality, color-matched print to 850 the world’s largest cities ... Supply Chain extends to 137 countries providing global enterprises ... the print procurement process from online order to real-world ...
(Date:3/3/2015)... 2015  Rosa & Co. LLC, a drug development ... research, today announced it has two posters scheduled to ... Pharmacology and Therapeutics meeting in New Orleans, ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   Bristol- ... describing a quantitative systems pharmacology approach for immuno-oncology drug ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that ... clinical trial to investigate the use of REOLYSIN(R) for patients with ... James Markert , Division Director of Neurosurgery, and Professor, Neurosurgery and ... , , ...
... Moffitt Cancer Center announces steadily growing interest in the ERCC1 ... Lung Cancer patients.  Each year, more than 200,000 Americans are diagnosed ... , ... response to cisplatin-based chemotherapy.   The correlation between ERCC1 levels and ...
... ... databases with the launching of PrescriberPRO@Home. This Database will allow marketers to send targeted ... or email address. , ... (Vocus) April 23, 2010 -- Healthcare Data Solutions (HDS) has recently ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial 2Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 2Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 4Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home. 2Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home. 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... frontier for pharmaceutical makers. Even after they discover a ... wonder drug, however, they have to confront a long-standing ... in a highly pure state. Now, a multi-institutional research ... Standards and Technology (NIST) may have found* a new ...
... polluting industrial processes can be made safer with enzymes. ... available for the chemical industry. , Recently a group ... of Copenhagen succeeded in producing an artificial enzyme that ... , With their group leader, Professor Mikael Bols, Ph.d. ...
... TORONTO, October 22, 2009 New research shows that ... a premature death unless they perform an adequate courtship ... research shows that "sneaker" males can slip by and ... first suitor. Scientists at the University of ...
Cached Biology News:Biochemical 'on-switch' could solve protein purification challenge 2New artificial enzyme safer for nature 2Male Australian redback spiders employ courtship strategies to preserve their life 2
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is ... be effective in inhibiting retroviral activity. ... BSA. Specificity: The specificity of ... ratio of the moles of ddC to moles ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
...
... Class II Biological Safety Cabinets provide ... comfort while incorporating the latest technology ... environment and product protection with dual ... air.,Bottom filters are safely exchanged under ...
Biology Products: